

# + Precision powered performance

Aiming for a new era of  
performance and value for the hip

**Smith+Nephew**



WEREWOLF<sup>+</sup>  
FASTSEAL 6.0  
Hemostasis Wand



HIP



# The data...

Total joint arthroplasty (TJA) is considered one of the most successful surgeries ever developed<sup>1</sup> and continuing to improve positive patient outcomes becomes ever more challenging.

However, in a systematic literature review, with meta-analysis comparing tissue-sparing with traditional approaches for total hip arthroplasty (THA), the data suggests the following...



## Blood loss

Intra-operative blood loss averaged 222ml in the tissue sparing approaches compared to 276ml in the traditional approaches<sup>\*2</sup>



## Blood transfusion

Among studies that reported blood loss outcomes, the average rate of blood transfusion was 8% (range 0-27.3%); with tissue sparing approaches averaging 7% (95% CI 4.21-10.76) and traditional approaches at 10% (95% CI 7.20-14.2).<sup>\*\*2</sup>



## Patient outcomes

A hemostasis wand offers an intra-operative solution that can be used as part of a comprehensive blood management protocol to aid transition to tissue sparing techniques, which has been shown to maintain similar blood-related patient outcomes than traditional techniques.<sup>2</sup>

## Value



As TJA procedures are now reimbursed in the lower dependency settings, surgeons who want to perform surgery on suitable patients are focusing not only on the patient outcomes but also the efficiency and value of the procedure.

\*Based on findings from 12 studies

\*\*Based on findings from 15 studies

# FASTSEAL 6.0 Hemostasis Wand

The WEREWOLF<sup>®</sup> FASTSEAL 6.0 Hemostasis Wand can be used for your open orthopedic procedures for hemostasis of soft tissue and bone.



Handle geometry includes grip features that minimize FASTSEAL 6.0 device slipping or rotating in the hand during use<sup>7</sup>



↓  
200°C  
less

The combination of saline and radiofrequency energy provides an average peak temperature of  $96 \pm 3^\circ\text{C}^*$  - approximately 200°C less than monopolar electrocautery<sup>3-5</sup>

Additionally, the FASTSEAL 6.0 device operates at a peak current limit of 1.5 Amps compared to 3.2 Amps for Aquamantys™ 6.0, to limit thermal energy potential of saline.<sup>6</sup>

\*One device tested 30 times

Shown to have less visible charring of soft tissue than a monopolar electrocautery device<sup>8\*\*</sup>

\*\*As demonstrated ex vivo at maximum setting, single device tested 30 times



Figure: Typical appearance of FASTSEAL 6.0 (left) and monopolar electrocautery device coagulation treatments in bovine myocardium (beef heart) soft tissue model.<sup>8</sup> (right)

# WEREWOLF<sup>◇</sup> Controller

Experience the power of the FASTSEAL 6.0 Wand using the WEREWOLF Controller, a single unit is available to use for all your Sports Medicine, ENT and orthopedic procedures.

The FASTSEAL 6.0 Wand requires less time between controller connection and activation than Aquamantys™ 6.0 with Aquamantys Pump Generator system<sup>9, 10\*</sup>


\*As per in the Aquamantys Pump Generator User Guide

## Flow rate

- Range of saline flow rate range from 1 (lowest) to 5 (highest)
- Default setting is 3

## Priming button

- On the WEREWOLF Controller, the FASTSEAL 6.0 Wand has been shown to prime in 14 seconds<sup>9, 10</sup>



## Coagulation level

- Rate of coagulation levels from 110 (lowest) to a maximum of 200 (highest)
- Default setting is 170



## Setting preferences

- Volume adjustment
- Language preferences
- Foot pedal and handpiece preferences

## Foot pedal plug-in

# Ordering information

WEREWOLF <sup>®</sup> FASTSEAL 6.0	
Reference	Description
72290146	WEREWOLF+ COBLATION <sup>®</sup> System
72290042	WEREWOLF FASTSEAL 6.0 Hemostasis Wand

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

Learn more at [smith-nephew.com](https://www.smith-nephew.com)

Distributed by:  
Smith & Nephew, Inc.  
150 Minuteman Road  
Andover, MA 01810  
USA

[www.smith-nephew.com](https://www.smith-nephew.com)  
T +978 749 1000  
US Customer Service:  
+1 800 343 5717

Manufactured by:  
ArthroCare Corporation  
7000 West William  
Cannon Drive  
Austin, TX 78735, USA

<sup>®</sup>Trademark of Smith+Nephew.  
All trademarks acknowledged.  
©2024 Smith+Nephew. All rights reserved. 33345 V2 12/24

## References

1. Knight SR, Aujla R, Biswas SP. Total Hip Arthroplasty - over 100 years of operative history. *Orthop Rev.* 2011; 3(2):e16. Published online 2011 Nov 7. doi: 10.4081/or.2011.e16
2. Smith+Nephew 2021. Systematic literature review to evaluate blood loss in total hip arthroplasty in the peri-operative period. Internal Report EA/SPM/COBLATION/008/v2
3. Marulanda GA, Ulrich SD, Seyler TM, Delanois RE, Mont MA. Reductions in blood loss with a bipolar sealer in total hip arthroplasty. *Expert Rev Med Devices.* 2008;5(2):125-131.
4. Derman PB, Kamath AF, Lee GC. Saline-coupled bipolar sealing in revision total knee arthroplasty for infection. *Am J Orthop (Belle Mead NJ).* 2013;42(9):407-411.
5. Smith+Nephew 2021. Report, Peak Temperature Comparative Study, FASTSEAL 6.0 and Aquamantys 6.0. Internal Report. 110180-02 Rev A. **6.** Smith+Nephew 2021. FASTSEAL 6.0 Wand Current Limit Safety Feature. Internal Report. 110183 Rev A. **7.** Smith+Nephew 2021. Arthroplasty Coagulation System Summative / Human Factors Validation. Internal Report. 110154-01 Rev A. **8.** Smith+Nephew 2021. Engineering Report, Soft Tissue Visual Charring Study, FASTSEAL 6.0 and Bovie-Style Device. Internal Report. 21-0005-01 Rev A. **9.** Smith+Nephew 2021. Design Verification Report: Challenge Condition, Expected Use & Every Tissue Every Level. Internal Report. 110127-01 Rev A. **10.** Smith+Nephew 2021. Priming time associated with the Aquamantys Pump Generator. Internal Report. EO.SPM.PCS.037.001.v1.